17,261 trials
Meibomian Gland Dysfunction · Blepharitis · Demodex Infestation
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 1; 1 Participants
HIV Infections
Primary: Monotherapy, VH4004280: Maximum Change From Baseline (Day 1) in Plasma HIV-1 Ribonucleic Acid (RNA) log10 — 5.004; 4.923; 4.866; 4.636 log10 c/mL
Influenza, Human · SARS-CoV-2 Infection · COVID-19
Primary: Percentage of Participants Who Reported Any Local Reaction up to 7 Days Following Vaccination — 56.3; 11.9; 59.0; 38.5 Percentage of participants
Hemophilia A
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 2; 2; 2; 5 Participants
Lung Cancer Metastatic · NSCLC Stage IV · Adenocarcinoma of Lung
Primary: Objective Response Rate (ORR) — 10; 0; 0; 10 Participants
Chronic Heart Failure With Reduced Ejection Fraction
Primary: Treatment Tolerability: Number of Participants Without Discontinuation of Study Intervention (Incl. Max. 1 Day Interruption) and Without Moderate to Severe Symptomatic…
Zika Virus
Primary: Number of Participants With Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs) — 86; 164; 183; 163 Participants
Campylobacter Infections
Primary: Number of Participants With Solicited or Unsolicited Adverse Events — 15; 16; 17; 16 Participants
Gastric Cancer
Primary: Overall Response Rate (ORR) in Subjects Treated With FLX475 in Combination With Pembrolizumab — 0; 60.0 percentage of participants
Cocaine-Related Disorders
Primary: Change in Orbitofrontal Cortex (OFC) BOLD Signal During Cocaine Cue Reactivity Task (Pre- vs. Post-TBS) — -0.0026; 0.0007 BOLD signal
Sickle Cell Disease · Anemia, Sickle Cell · Anemia, Hemolytic, Congenital
Primary: Annual Rate of Respiratory Events — 3.3; 3.3; 3.4; 3.2 Respiratory events per year
Idiopathic Pulmonary Fibrosis
Primary: Primary Outcome — -0.0147; 0.0740 Unitless
Osteoporosis · Bone Loss · Osteopenia, Osteoporosis
Primary: Change in Integral vBMC at the Knee (Distal Femur) — -0.78 g
Classical Hodgkin Lymphoma
Primary: Overall Response Rate (ORR) — 64.3; 64.5; 64.4 Percentage of Participants — p=0.0044
Adjunctive Treatment of Major Depressive Disorder
Primary: Part B - Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score — -10.72; -9.46 units on a scale — p=0.46